We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-3 of 3

Radiopharmacies Celebrate the New Year with Long-Awaited FDA Guidance
  • Reed Smith LLP
  • USA
  • December 31 2016

On December 29, 2016, the U.S. Food and Drug Administration (“FDA”) surprised many in the radiopharmacy industry by issuing a long-awaited draft


Prescription drug and medical device promotion new FDA draft guidance on presenting risk information
  • Reed Smith LLP
  • USA
  • June 2 2009

On May 27, 2009, the Food and Drug Administration ("FDA") announced the availability of a draft guidance titled Presenting Risk Information in Prescription Drug and Medical Device Promotion ("Draft Guidance").